

Nemaura Medical Inc

12:30 18 Sep 2020

Nemaura Medical appoints Justin Mclarney as chief finance officer

Nemaura Medical Inc (NASDAQ:NMRD), which is developing and commercializing its diabetes diagnostic devices and subscription services, has appointed Justin Mclarney as chief finance officer.

In a statement Friday, CEO Dr Faz Chowdhury called Mclarney an "invaluable asset" to the group's leadership team as it continues to grow and execute on its business model.

"His proven track record of driving financial and operational success throughout his career inspires strong confidence as we approach the commercialization phase of our corporate trajectory," Chowdhury said.

READ: Nemaura Medical banks \$18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services

Nemaura said Mclarney brings with him a wealth of experience within international finance, accounting, and process development & control and has been a chartered accountant since 1999. He has a strong track record of driving profitable growth across businesses encompassing ecommerce, retail, logistics, and supply chain operations at an international level.

Mclarney, who started on September 15, has held various senior finance and operational roles, including most recently the position of senior director, international finance at Lands' End Inc from January 2016 to May 2020 where he was responsible for all finance teams across the European and Japanese business units.

From February 2007 to September 2015, Mclarney worked for Office Depot in a range of increasingly senior roles culminating in the senior director of finance for the European Contract business. Prior, he spent over 10 years in practice, the final seven years of which was with Ernst & Young LLP.

Mclarney said: "I am very happy to be joining Nemaura Medical at such an exciting time. Nemaura has been developing a very exciting platform over a number of years that offers huge potential to directly improve the lives of millions of people both with regard to diabetes as well as other broader and far-reaching health and lifestyle improvements. I look forward to working with Faz and the team as we build and evolve the business to deliver its commercial vision across an International footprint."


Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 3.83

Market Cap: \$87.74 m

1 Year Share Price Graph



December 2019 June 2020 December 20

Share Information

Code: NMRD

Listing: NASDAQ

52 week High Low
16.35 2.5

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).